z-logo
open-access-imgOpen Access
Successful long-term control of Cushing’s disease after partial resection of gigantic ACTH-secreting pituitary adenoma
Author(s) -
Vatroslav Čerina,
Luigi Maria Cavallo,
Ivan Kruljac,
Jelena Marinković Radošević,
Darko Stipić,
Hrvoje Ivan Pećina,
Leo Pažanin,
Milan Vrkljan
Publication year - 2016
Publication title -
endocrine oncology and metabolism
Language(s) - English
Resource type - Journals
eISSN - 1849-8922
pISSN - 1849-9031
DOI - 10.21040/eom/2016.2.10
Subject(s) - cushing's disease , resection , pituitary adenoma , term (time) , adenoma , medicine , adrenocorticotropic hormone , disease , surgery , hormone , physics , quantum mechanics
Only 4-9% of patients with Cushing’s disease (CD) harbor pituitary macroadenomas. Clinical and biochemical features of macrocorticotropinomas are poorly understood. Some evidence exist that these tumors presents clinical features more similar to a non-functioning adenomas, being though defined silent corticotropinomas, rather than to ACTH-secreting adenomas. In this paper, we report a case of a 60-year old woman with a history of obesity, arterial hypertension and diabetes mellitus who presented with overt central hypothyroidism. Magnetic resonance imaging disclosed giant pituitary adenoma measuring 50 mm. Endocrinological evaluation confirmed CD: ACTH 50.3 pmol/L, urinary free-cortisol of 739 nmol/24h and cortisol of 639 nmol/L after 1 mg dexamethasone suppression test. Tumor mass was reduced by 50% using purely endoscopic transsphenoidal approach. Thirty-eight months after the partial resection, the patient had well controlled CD: ACTH 20.2 pmol/L, urinary free-cortisol of 238 nmol/24h, cortisol of 105 nmol/L after 1 mg dexamethasone suppression test. To the best of our knowledge, this is the largest ACTH-secreting adenoma ever reported. Our case suggests that tumor size does not necessarily correlate with aggressiveness of CD in patients with macrocorticotropinomas and that long-term control of CD may be achieved albeit incomplete surgical removal. Further studies are needed in order to determine the best treatment option for patients with macrocorticotropinomas.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom